Vertex Pharmaceuticals

CEO Reshma Kewalramani has executed on CF lifecycle, navigated gene therapy approvals and brought a first‑in‑class acute pain drug to market.

Leadership transitions appear planned and orderly, with CFO Charlie Wagner taking on COO responsibilities in 2025 and a staged CSO transition through 2026. Setbacks such as the 2025 pain asset discontinuation and the VX‑264 impairment were acknowledged promptly and capital was re‑channeled, consistent with a rational, long‑term orientation.